

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID NO:30);

(b) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 30 (SEQ ID NO:30);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide;~~

~~(c)~~(e) the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29);

~~(d)~~(f) the full-length coding sequence of the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29); or

~~(e)~~(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 203174;

wherein said isolated nucleic acid is more highly expressed in normal lung tissue or kidney tumor compared to lung tumor or normal kidney tissue respectively, or wherein said isolated nucleic acid encodes a polypeptide that is more highly expressed in normal lung tissue or kidney tumor compared to lung tumor or normal kidney tissue respectively.

2. (Currently Amended) The isolated nucleic acid of Claim 1 having at least 85% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID NO:30);

(b) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 30 (SEQ ID NO:30);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide;~~

~~(c)~~(e) the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29);

Appl. No. : 10/063,685
Filed : May 8, 2002

~~(d)(f)~~ the full-length coding sequence of the nucleic acid sequence of shown in Figure 29
(SEQ ID NO:29); or

~~(e)(g)~~ the full-length coding sequence of the cDNA deposited under ATCC accession
number 203174;

wherein said isolated nucleic acid is more highly expressed in normal lung tissue or
kidney tumor compared to lung tumor or normal kidney tissue respectively, or wherein said
isolated nucleic acid encodes a polypeptide that is more highly expressed in normal lung tissue or
kidney tumor compared to lung tumor or normal kidney tissue respectively.

3. (Currently Amended) The isolated nucleic acid of Claim 1 having at least 90% nucleic
acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID
NO:30);

(b) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID
NO:30), lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in
Figure 30 (SEQ ID NO:30);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown
in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide;~~

~~(c)(e)~~ the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29);

~~(d)(f)~~ the full-length coding sequence of the nucleic acid sequence of shown in Figure 29
(SEQ ID NO:29); or

~~(e)(g)~~ the full-length coding sequence of the cDNA deposited under ATCC accession
number 203174;

wherein said isolated nucleic acid is more highly expressed in normal lung tissue or
kidney tumor compared to lung tumor or normal kidney tissue respectively, or wherein said
isolated nucleic acid encodes a polypeptide that is more highly expressed in normal lung tissue or
kidney tumor compared to lung tumor or normal kidney tissue respectively.

4. (Currently Amended) The isolated nucleic acid of Claim 1 having at least 95% nucleic
acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID
NO:30);

Appl. No. : 10/063,685
Filed : May 8, 2002

(b) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide;

~~(e) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 30 (SEQ ID NO:30);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide;~~

~~(c)~~(e) the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29);

~~(d)~~(f) the full-length coding sequence of the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29); or

~~(e)~~(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 203174;

wherein said isolated nucleic acid is more highly expressed in normal lung tissue or kidney tumor compared to lung tumor or normal kidney tissue respectively, or wherein said isolated nucleic acid encodes a polypeptide that is more highly expressed in normal lung tissue or kidney tumor compared to lung tumor or normal kidney tissue respectively.

5. (Currently Amended) The isolated nucleic acid of Claim 1 having at least 99% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID NO:30);

(b) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide;

~~(e) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 30 (SEQ ID NO:30);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide;~~

~~(c)~~(e) the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29);

~~(d)~~(f) the full-length coding sequence of the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29); or

~~(e)~~(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 203174;

Appl. No. : 10/063,685
Filed : May 8, 2002

wherein said isolated nucleic acid is more highly expressed in normal lung tissue or kidney tumor compared to lung tumor or normal kidney tissue respectively, or wherein said isolated nucleic acid encodes a polypeptide that is more highly expressed in normal lung tissue or kidney tumor compared to lung tumor or normal kidney tissue respectively.

6. (Currently Amended) An isolated nucleic acid comprising:

(a) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID NO:30);

(b) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 30 (SEQ ID NO:30);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide;~~

~~(c)~~(e) the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29);

~~(d)~~(f) the full-length coding sequence of the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29); or

~~(e)~~(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 203174.

7. (Currently Amended) The isolated nucleic acid of Claim 6 comprising a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID NO:30).

8. (Currently Amended) The isolated nucleic acid of Claim 6 comprising a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide.

9. (Canceled).

10. (Canceled).

11. (Currently Amended) The isolated nucleic acid of Claim 6 comprising the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29).

12. (Currently Amended). The isolated nucleic acid of Claim 6 comprising the full-length coding sequence of the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29).

13. (Original) The isolated nucleic acid of Claim 6 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 203174.

Appl. No. : 10/063,685
Filed : May 8, 2002

14. (Currently Amended) An isolated nucleic acid that hybridizes under stringent conditions to:

(a) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID NO:30);

(b) a nucleic acid sequence encoding the polypeptide of shown in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 30 (SEQ ID NO:30);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 30 (SEQ ID NO:30), lacking its associated signal peptide;~~

~~(c)~~(e) the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29);

~~(d)~~(f) the full-length coding sequence of the nucleic acid sequence of shown in Figure 29 (SEQ ID NO:29); or

~~(e)~~(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 203174;

wherein said stringent conditions comprise 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

15. (Canceled).

16. (Original) The isolated nucleic acid of Claim 14 which is at least 10 nucleotides in length.

17. (Original) A vector comprising the nucleic acid of Claim 1.

18. (Original) The vector of Claim 17, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

19. (Original) A host cell comprising the vector of Claim 17.

20. (Original) The host cell of Claim 19, wherein said cell is a CHO cell, an E. coli or a yeast cell.

Appl. No. : **10/063,685**
Filed : **May 8, 2002**

DELETION OF INVENTORS

Please correct the inventorship under 37 CFR §1.48(b) by removing the following inventors from the present application:

Dan L. Eaton, Ellen Filvaroff, Mary E. Gerritsen, and Colin K. Watanabe.